The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, while an older term, continue to capture attention as they often represent smaller or newer companies that provide growth opportunities at lower price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover potential gems within this niche area of the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$2.88	$180.1M	✅ 3 ⚠️ 2 View Analysis >
LexinFintech Holdings (LX)	$2.02	$341.11M	✅ 3 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.17	$1.38B	✅ 4 ⚠️ 1 View Analysis >
FinVolution Group (FINV)	$4.94	$1.25B	✅ 4 ⚠️ 1 View Analysis >
Information Services Group (III)	$3.11	$203.8M	✅ 3 ⚠️ 0 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$3.80	$300.09M	✅ 3 ⚠️ 1 View Analysis >
Village Farms International (VFF)	$2.64	$297.15M	✅ 5 ⚠️ 1 View Analysis >
BAB (BABB)	$0.9416	$6.91M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$4.975	$10M	✅ 2 ⚠️ 3 View Analysis >

Let's uncover some gems from our specialized screener.

Hongli Group (HLP)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Hongli Group Inc., along with its subsidiaries, manufactures and sells customized metal profiles in China and internationally, with a market cap of $86.70 million.

Operations: No revenue segments have been reported.

Market Cap: $86.7M

Hongli Group Inc. has recently reported a significant turnaround with annual sales reaching US$19.6 million and net income of US$1.94 million, marking profitability compared to the previous year's loss. Despite this positive development, the company faces challenges such as volatile share prices and delayed SEC filings, which may concern investors about transparency and stability. The company's debt management shows improvement with a satisfactory net debt to equity ratio of 16.8%, although operating cash flow coverage remains weak at 7.6%. A recent private placement raised US$325,000, potentially supporting future operations or strategic initiatives.

Lantern Pharma (LTRN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Lantern Pharma Inc. is engaged in the discovery and development of oncology drugs in India, with a market cap of $28.13 million.

Operations: Lantern Pharma does not report any revenue segments.

Market Cap: $28.13M

Lantern Pharma Inc., with a market cap of US$28.13 million, is pre-revenue and focused on oncology drug development using AI-driven platforms. The recent US$4.4 million equity offering aims to bolster its cash runway beyond the current eight months. Despite no debt and experienced management, Lantern's financials show increased losses over five years and forecasted earnings decline by 9.6% annually for three years. The launch of the withZeta.ai platform introduces potential non-dilutive revenue streams through subscriptions, yet profitability remains elusive as it navigates a volatile share price environment and auditor concerns about its going concern status persist.

Spero Therapeutics (SPRO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for multi-drug resistant bacterial infections and rare diseases in the United States, with a market cap of $141.28 million.

Operations: Spero Therapeutics, Inc. does not report any specific revenue segments.

Market Cap: $141.28M

Spero Therapeutics, Inc., with a market cap of US$141.28 million, has transitioned to profitability and reported significant revenue growth last year but experienced a decline in the recent quarter. Despite this volatility, its strong balance sheet shows short-term assets exceeding liabilities and no debt burden. The company’s high return on equity of 28.8% reflects efficient capital use, while its seasoned management and board bolster strategic direction. Recent amendments to increase authorized shares signal potential future capital raising activities as it navigates the competitive biotech landscape with innovative treatments for resistant infections and rare diseases.

Where To Now?

• Click through to start exploring the rest of the 355 US Penny Stocks now.
• Interested In Other Possibilities? These 22 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.